Published in J Pharm Sci on January 01, 1975
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother (1997) 2.31
5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci U S A (1993) 1.02
Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. Antimicrob Agents Chemother (1993) 0.92
Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. Antimicrob Agents Chemother (1995) 0.90
In vivo quantitative assessment of catheter patency in rats. Lab Anim (2005) 0.90
Metabolic disposition and pharmacokinetics of the antiviral agent 6-methoxypurine arabinoside in rats and monkeys. Antimicrob Agents Chemother (1991) 0.87
The effects of hypoglycin on glucose metabolism in the rat. A kinetic study in vivo and [U-14C,2-3H]glucose. Biochem J (1978) 0.86
Transplacental stimulation of lung development in the fetal rabbit by 3,5-dimethyl-3'-isopropyl-L-thyronine. J Clin Invest (1980) 0.81
Disposition of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl-14C]S-1108 in rats and dogs. Antimicrob Agents Chemother (1995) 0.75
Metabolism and pharmacokinetics of the anti-varicella-zoster virus agent 6-dimethylaminopurine arabinoside. Antimicrob Agents Chemother (1992) 0.75
Wound tissue oxygen tension predicts the risk of wound infection in surgical patients. Arch Surg (1997) 2.02
Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet (1984) 1.96
Bioavailability of sublingual buprenorphine. J Clin Pharmacol (1997) 1.21
Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend (2000) 1.15
Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS. J Infect Dis (1986) 1.15
Intraindividual variability in theophylline pharmacokinetics: statistical verification in 39 of 60 healthy young adults. J Pharmacokinet Biopharm (1982) 1.14
Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine. J Pharm Sci (1980) 1.14
Pentamidine pharmacokinetics in patients with AIDS with impaired renal function. J Infect Dis (1987) 1.10
Determination of quinidine and its major metabolites by high-performance liquid chromatography. J Chromatogr (1979) 1.06
Naproxen pharmacokinetics in the elderly. Br J Clin Pharmacol (1984) 1.01
Ketoprofen-aspirin interactions. Clin Pharmacol Ther (1981) 0.99
Effects of probenecid on ketoprofen kinetics. Clin Pharmacol Ther (1982) 0.99
Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. J Pharmacokinet Biopharm (1979) 0.98
Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol (1999) 0.96
Tissue oxygen tension and other indicators of blood loss or organ perfusion during graded hemorrhage. Surgery (1991) 0.94
Ketoprofen pharmacokinetics and bioavailability based on an improved sensitive and specific assay. Eur J Clin Pharmacol (1981) 0.94
Determination of quinidine and metabolites in urine by reverse-phase high-pressure liquid chromatography. Clin Chim Acta (1979) 0.93
Convenient and sensitive high-performance liquid chromatography assay for ketoprofen, naproxen and other allied drugs in plasma or urine. J Chromatogr (1980) 0.93
Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (1988) 0.89
Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure. Br J Anaesth (1981) 0.88
Evaluation of the absorption from 15 commercial theophylline products indicating deficiencies in currently applied bioavailability criteria. J Pharmacokinet Biopharm (1980) 0.88
Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man. J Pharmacokinet Biopharm (1984) 0.87
Naproxen disposition in patients with alcoholic cirrhosis. Eur J Clin Pharmacol (1984) 0.85
Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function. Clin Pharmacol Ther (1986) 0.82
The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies. J Pharmacokinet Biopharm (1986) 0.82
Measurement of excretion characteristics of theophylline and its major metabolites. Eur J Clin Pharmacol (1981) 0.82
Lack of correlation of clinical breast examination with high-risk histopathology. Am J Med (1990) 0.80
Convenient and sensitive high-performance liquid chromatography assay for cimetidine in plasma or urine. J Chromatogr (1981) 0.78
Improved liquid-chromatography of aspirin, salicylate, and salicyluric acid in plasma, with a modification for determining aspirin metabolites in urine. Clin Chem (1982) 0.77
Effects of formulation and food on the absorption of hydrochlorothiazide and triamterene or amiloride from combination diuretic products. Pharm Res (1987) 0.77
Specific and sensitive assay of celiprolol in blood, plasma and urine using high-performance liquid chromatography. J Chromatogr (1982) 0.76
Improved acetaminophen assay sensitivity by modification of a high-performance liquid chromatography technique. J Chromatogr (1982) 0.75
Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods. J Pharmacokinet Biopharm (1979) 0.75
A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow. Br J Clin Pharmacol (1989) 0.75
Bioequivalence study of a new tablet formulation of triamterene and hydrochlorothiazide. Am J Med (1984) 0.75
Development of a new controlled-release formulation of chlorpheniramine maleate using in vitro/in vivo correlations. J Pharm Sci (1991) 0.75
Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered. J Pharmacokinet Biopharm (1984) 0.75
Pharmacokinetics of Aryldihydro-s-triazines with antifolate activity II: Blood levels and their relevance to antineoplastic activity in rats. J Pharm Sci (1978) 0.75
An integrated approach to measurements of quinidine and metabolites in biological fluids. J Chromatogr (1980) 0.75
Digital cutaneous fluorometry: correlation between blood flow and fluorescence. J Vasc Surg (1984) 0.75
Evaluation of the absorption from some commercial enteric-release theophylline products. J Pharmacokinet Biopharm (1980) 0.75
High-performance liquid chromatography assay of acebutolol and two of its metabolites in plasma and urine. J Chromatogr (1982) 0.75
Renal and biliary elimination of vecuronium (ORG NC 45) and pancuronium in rats. Anesth Analg (1982) 0.75
Evaluation of the absorption from some commercial sustained-release theophylline products. J Pharmacokinet Biopharm (1980) 0.75
Relationship between skin fluorescence and blood flow in normal and in chronically ischemic subjects dosed with fluorescein. J Pharm Sci (1991) 0.75
Relative bioavailability of two sustained-release theophylline formulations versus an immediate-release preparation. J Asthma (1983) 0.75
Evaluation of a modified high-performance liquid chromatography assay for acebutolol and its major metabolite. J Chromatogr (1979) 0.75
A method for estimating within-individual variability in clearance and in volume of distribution from standard bioavailability studies. J Pharmacokinet Biopharm (1982) 0.75
Gastrointestinal absorption of quinidine from some solutions and commercial tablets. J Pharmacokinet Biopharm (1980) 0.75
Pharmacokinetics of aryldihydro-s-triazines with antifolate activity I: metabolism and excretion by rats. J Pharm Sci (1978) 0.75
The clinical pharmacology of ketoprofen. J Clin Pharmacol (1988) 0.75
A theophylline dosage regimen which reduces round-the-clock variations in plasma concentrations resulting from diurnal pharmacokinetic variation. Eur J Clin Pharmacol (1987) 0.75